Proceedings of the International scientific and practical conference ―Science at the Frontier of Civilizations‖ (March 16-18, 2026) / Publisher website: www.naukainfo.com. – Helsinki, Finland, 2026. - 145 p.

9 Table 1. Somatic gene mutations in myeloproliferative neoplasms (MPN) and secondary acute myeloid leukemia (AML) GENE FUNC-TION FREQUENCY IN CLINICAL MANIFESTA TION PV ЕТ PMF POST MPN/ AML TET2 Epigenetic regulation 10%-20% 3%-10% 10%-20% 19%-25% No progno-stic impact reported DNMT3 A Epigenetic regulation 5%-10% 1%-5% 8%-12% 3%-17% No progno-stic impact reported IDH1 Epigenetic regulation 1%-2% 1%-2% 5%-6% 13% Metabolic enzyme mu- tations. Inc- reases risk of leukemic tra- nsformation, associated with worse survival. IDH2 Epigenetic regulation 1%-2% 1%-2% 5%-6% 7%-15% Metabolic enzyme mu- tations. Inc- reases risk of leukemic tra- nsformation, associated with worse survival. ASXL1 Epigenetic regulation 2%-7% 5%-10% 15%-35% 17%-47% Often asso- ciated with myelofibrosis. Presence of mutation wo- rsens prog- nosis, incre- ases risk of transformation to AML, associated with worse survival.